Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELI-002 2P · 1 trial · 12 indications
The safety of ELI-002 was monitored through adverse events, including those considered related to treatment by the investigator
| Arm | Type | Description |
|---|---|---|
| ELI-002 2P Cohort 1 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via subcutaneous (SC) injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 2 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 3 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 4 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (5.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| ELI-002 2P Cohort 5 | EXPERIMENTAL | ELI-002 2P Amph-CpG-7909 (10.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
| Name | Type | Description |
|---|---|---|
| ELI-002 2P | DRUG | Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing) |
Inclusion Criteria: * KRAS/NRAS mutated (G12D or G12R) solid tumor * Positive for circulating tumor DNA (ctDNA) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable * Screening CT is negative for recurrent disease...
ELI-002 2P is an investigational cancer therapy being developed by Elicio Therapeutics, Inc. (ELTX) for minimal residual disease in KRAS-mutated solid tumors. It is a small molecule designed to target KRAS and is in Phase 1 clinical development.
ELI-002 2P is being studied for the treatment of minimal residual disease in patients with KRAS-mutated solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, ovarian cancer, cholangiocarcinoma, bile duct cancer, and gallbladder carcinoma.
ELI-002 2P targets KRAS, specifically KRAS G12D and G12R mutations, as well as NRAS G12D and G12R mutations. It is a small molecule designed to address these specific genetic alterations in solid tumors.
ELI-002 2P is being developed by Elicio Therapeutics, Inc., which trades on the Nasdaq under the ticker symbol ELTX. The company is focused on advancing this therapy for KRAS-mutated cancers.
ELI-002 2P is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 1 trial has been completed.
ELI-002 2P has been evaluated in a Phase 1 clinical trial, NCT04853017, titled "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors." The trial enrolled 25 participants and has been completed.